Table 3.

List of potential compounds for repurposing with anti-Zika activity, extracted from [19, 83]

Drug group	Drug name	Description
Nucleoside analogs	Sofosbuvir, MK-608	• Inhibit Zika virus (ZIKV) replication in cellular assays • Efficacious in animal models
	2CMC, Ribavirin, Favipiravir, T1105	• Showed antiviral activity in cell culture
	BCX4430, GS5734	• Reduced mortality in ZIKV-infected mice • Currently in phase I and II clinical trials
Peptidomimetic agents	CN-716	• Inhibit ZIKV protease in vitro, but only weakly inhibit viral replication • Due to safety reasons, may not translate as therapeutic option for pregnant women, but could be applied to other infected individuals
Adenosine analog	NITD008	• Showed potent anti-ZIKV activity • Could serve as a reference inhibitor for future drug screen and discovery
Cyclin-dependent kinase inhibitor	PHA-690509	• Showed inhibition of ZIKV replication of all three strains
Antimalaria	Chloroquine	• Reduces virus production, the number of infected cells, and cell death promoted by ZIKV infection without any cytotoxic effect • Promising candidate for ZIKV clinical trials • Can be safely administered to pregnant women since it is clinically approved
Anthelmintic	Bithionol	• Propagate by activating host caspases and inducing programmed cell death
Epigallocatechin gallate		• Natural compound found in food items, particularly green tea • It inhibits ZIKV entry into host cell
Interferon-inducible transmembrane proteins		• Inhibit the replication of a number of pathogenic viruses